Combinations Of Cabozantinib And Atezolizumab To Treat Cancer

Patent No. EP3570840 (titled "Combinations Of Cabozantinib And Atezolizumab To Treat Cancer") was filed by Exelixis on Jan 19, 2018. The application was issued on Mar 19, 2025.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Company	Opposition Date	Representative
STADA ARZNEIMITTEL	Dec 19, 2025	HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

Date
Description

Get instant alerts for new documents

Jan 12, 2026
Communication of a notice of opposition and request to file observations
Jan 12, 2026
Notice of further oppositions to opponent(s)
Jan 5, 2026
Communication of a notice of opposition - first information to patent proprietor
Dec 19, 2025
(Electronic) Receipt
Dec 19, 2025
Citation in opposition procedure - 001
Dec 19, 2025
Citation in opposition procedure - 002
Dec 19, 2025
Citation in opposition procedure - 003
Dec 19, 2025
Citation in opposition procedure - 004
Dec 19, 2025
Citation in opposition procedure - 005
Dec 19, 2025
Citation in opposition procedure - 006
Dec 19, 2025
Consolidated list of cited opposition documents
Dec 19, 2025
Notice of opposition
Dec 19, 2025
Notice of opposition
Apr 1, 2025
Transmission of the certificate for a European patent pursuant to Rule 74 EPC
Mar 10, 2025
Communication of amended entries concerning the representative
Mar 5, 2025
(Electronic) Receipt
Mar 5, 2025
Request for change of applicant's representative
Feb 20, 2025
Decision to grant a European patent
Feb 17, 2025
Decision to allow further processing
Feb 11, 2025
(Electronic) Receipt
Feb 11, 2025
French translation of claims
Feb 11, 2025
German translation of the claims
Feb 11, 2025
Letter accompanying subsequently filed items
Feb 11, 2025
Request for further processing
Dec 11, 2024
Application deemed to be withdrawn ( translations of claims/payment missing)
Jul 25, 2024
Annex to the communication about intention to grant a European patent
Jul 25, 2024
Bibliographic data of the European patent application
Jul 25, 2024
Communication about intention to grant a European patent
Jul 25, 2024
Intention to grant (signatures)
Jul 25, 2024
Text intended for grant (clean copy)
Jul 25, 2024
Text intended for grant (version for approval)
Jul 11, 2024
Decision to allow further processing
Jul 4, 2024
(Electronic) Receipt
Jul 4, 2024
Amended description with annotations
Jul 4, 2024
Description
Jul 4, 2024
Letter accompanying subsequently filed items
Jul 4, 2024
Request for further processing
May 8, 2024
Application deemed to be withdrawn ( translations of claims/payment missing)
Dec 14, 2023
Annex to the communication about intention to grant a European patent
Dec 14, 2023
Bibliographic data of the European patent application
Dec 14, 2023
Communication about intention to grant a European patent
Dec 14, 2023
Intention to grant (signatures)
Dec 14, 2023
Text intended for grant (clean copy)
Dec 14, 2023
Text intended for grant (version for approval)
Aug 8, 2023
(Electronic) Receipt
Aug 8, 2023
Amended claims with annotations
Aug 8, 2023
Amended description with annotations
Aug 8, 2023
Claims
Aug 8, 2023
Description
Aug 8, 2023
Letter accompanying subsequently filed items
Aug 8, 2023
Reply to communication from the Examining Division
Jun 14, 2023
Grant of extension of time limit (examination procedure)
Jun 8, 2023
(Electronic) Receipt
Jun 8, 2023
Letter accompanying subsequently filed items
Jun 8, 2023
Request for extension of time limit to communication from the Examining Division
Mar 29, 2023
Annex to the communication
Mar 29, 2023
Communication from the Examining Division
Dec 9, 2022
(Electronic) Receipt
Dec 9, 2022
Amended claims with annotations
Dec 9, 2022
Claims
Dec 9, 2022
Letter accompanying subsequently filed items
Dec 9, 2022
Non-patent literature cited during the examination procedure
Dec 9, 2022
Non-patent literature cited during the examination procedure
Dec 9, 2022
Reply to communication from the Examining Division
Nov 4, 2022
Grant of extension of time limit (examination procedure)
Oct 28, 2022
(Electronic) Receipt
Oct 28, 2022
Letter accompanying subsequently filed items
Oct 28, 2022
Request for extension of time limit to communication from the Examining Division
Sep 2, 2022
Grant of extension of time limit (examination procedure)
Aug 30, 2022
(Electronic) Receipt
Aug 30, 2022
Letter accompanying subsequently filed items
Aug 30, 2022
Request for extension of time limit to communication from the Examining Division
Jun 21, 2022
Annex to the communication
Jun 21, 2022
Communication from the Examining Division
Apr 22, 2021
(Electronic) Receipt
Apr 22, 2021
Amended claims with annotations
Apr 22, 2021
Claims
Apr 22, 2021
Letter accompanying subsequently filed items
Apr 22, 2021
Non-patent literature cited during the examination procedure
Apr 22, 2021
Non-patent literature cited during the examination procedure
Apr 22, 2021
Reply to communication from the Examining Division
Feb 26, 2021
Grant of extension of time limit (examination procedure)
Feb 22, 2021
(Electronic) Receipt
Feb 22, 2021
Letter accompanying subsequently filed items
Feb 22, 2021
Request for extension of time limit to communication from the Examining Division
Jan 21, 2021
Document concerning representation
Jan 21, 2021
Document concerning representation
Jan 21, 2021
Letter accompanying subsequently filed items
Oct 13, 2020
Annex to the communication
Oct 13, 2020
Communication from the Examining Division
Oct 7, 2020
Examination started
Jul 14, 2020
Decision to allow further processing
Jun 26, 2020
(Electronic) Receipt
Jun 26, 2020
Amended claims filed after receipt of (European) search report
Jun 26, 2020
Amended claims with annotations
Jun 26, 2020
Letter accompanying subsequently filed items
Jun 26, 2020
Request for further processing
Apr 16, 2020
Application deemed to be withdrawn (non-reply to Written Opinion)
Apr 16, 2020
Claim deemed abandoned
Oct 30, 2019
Notification on forthcoming publication of bibliographic data
Aug 27, 2019
Communication concerning correction of deficiencies in written opinion/amendment of application/payment of claims fee
Aug 23, 2019
Communication to designated inventor
Aug 23, 2019
Communication to designated inventor
Aug 23, 2019
Communication to designated inventor
Aug 6, 2019
Copy of the international preliminary report on patentability
Jul 31, 2019
(Electronic) Receipt
Jul 31, 2019
Request for entry into the European phase
Jul 31, 2019
Submission concerning representation
Jul 18, 2019
Notification of the recording of a change
Jul 18, 2019
Notification of the recording of a change
Jun 3, 2019
Information on entry into European phase
Aug 15, 2018
Priority document (electronically transmitted)
Aug 15, 2018
Priority document (electronically transmitted)
Jul 26, 2018
Copy of the international search report
Jul 26, 2018
Published international application - A1
May 7, 2018
ISR: cited documents
May 4, 2018
Written opinion of the ISA, boxes No. I to VIII
May 4, 2018
Written opinion of the ISA, cover sheet
May 4, 2018
Written opinion of the ISA, supplemental box
Mar 20, 2018
Notification of receipt of Search copy
Mar 6, 2018
Abstract
Mar 6, 2018
Annex
Mar 6, 2018
Claims
Mar 6, 2018
Description
Mar 6, 2018
Incoming letter related to ISA procedure
Mar 6, 2018
Incoming letter related to ISA procedure
Mar 6, 2018
Notification Concerning Payment of Prescribed Fees (copy for ISA/EP)
Mar 6, 2018
Notification of the International Application Number and of the International Filing Date (copy for ISA/EP)
Mar 6, 2018
Request form for international application (copy for ISA/EP)
Mar 6, 2018
Submission concerning representation

EP3570840

EXELIXIS

Application Number: EP18709192A
Filing Date: Jan 19, 2018
Status: Granted And Under Opposition; Feb 14, 2025
Publication Date: Mar 19, 2025
External Links: Slate, Register , Google Patents

IP Verse

Combinations Of Cabozantinib And Atezolizumab To Treat Cancer

Patent Summary

Patent Family

Patent Oppositions

Dossier Documents

EP3570840